Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026

뉴스 본문을 불러오고 있어요.

Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026 | 웨이프 WAPE

Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026

기사 요약

관련 종목

댓글 —